Searched for
DIABETES MARKET
These large- and mid-cap stocks can give more than 20% return in 1 year, according to analystsIn just a few days, the Q1 earnings season for FY27 will start. But before that will come the season of business updates. And that needs to...- Energy drinks or sports drinks? : Top neurologist explains the key difference you’re missing and how it affecrs your bodyHyderabad neurologist Dr. Sudhir Kumar clarifies that energy drinks primarily offer caffeine and sugar, not true energy for workouts. He em...
- Shantha Biologics to Make Injectable Drug Cartridges for Novo NordiskShantha Biologics has secured a significant contract with Danish pharmaceutical giant Novo Nordisk to manufacture cartridges for injectable...
- 'Cheaper than a gym, but still not selling': Nithin Kamath on why Indians aren't embracing popular weight-loss drugsDespite rising obesity and affordable generic GLP-1 drugs, India lags in adoption. Nithin Kamath highlights patient retention challenges wi...
- For investors looking beyond the short-term horizon: 5 mid-cap stocks from different sectors with upside potential up to 28%All is once again quiet on the US-Iran war front, and some kind of dialogue to resolve the issues between the two seems to be still underwa...
- My wife and I declared diabetes in our health insurance policy. Will it cover new illnesses too?ET Wealth Reader's Query: My wife and I have had a floater health insurance policy for over four years. We declared diabetes as a pre-exist...
- Should they now be part of a long-term investing framework? 7 healthcare stocks with upside potential of up to 25%India’s healthcare market may grow steadily, but hospital chains can grow faster as formalisation continues. Healthcare is all about market...
- For investors with ability – and patience to wait 3 years, not 3 months: 6 large-cap stocks with upside potential of up to 33%The interesting point about the large-cap space today is not that prices have collapsed. In most cases, they have not. The more important c...
- The emperor's new biomarker? Another wearable for us to evaluateA new wearable biomarker, 'Entropy,' measuring body energy consumption, has stirred the bio-hacking community. While the name is catchy, th...
- Kiran Mazumdar-Shaw warns against long-term GLP-1 use, urges caution over weight-loss drugs, says 'for those who are not diabetic or clinically obese...'Nithin Kamath questions India's slow adoption of affordable GLP-1 weight-loss drugs, despite rising obesity. He points to challenges like l...
- Healthcare demand is outstripping supply in Noida, says MOFSL; prefers Medanta, Max HealthcareNoida-Greater Noida is rapidly becoming a prime healthcare hub in North India, fueled by population growth and corporate expansion. Despite...
- These large-, mid- and small-cap stocks can give more than 25% return in 1 year, according to analystsAs the old saying goes: Nothing can be ruled out on the street. Which means that one should be prepared for anything. Now, what is the prob...
- India has Rs 95,000 cr addressable market for assistive tech by 2030: NCPEDPIndia's assistive technology market could reach Rs 95,000 crore by 2030 with a dedicated national policy, experts revealed. This sector, cr...
- Scanning cancer, up close & personal: A revolution is underway in cancer diagnosisA gene-based test called next-generation sequencing can identify precise mutations, which can then be treated with targeted therapies. Sinc...
- GI tag puts Mandu's Khurasani Imli on the global mapMandu's unique Khurasani Imli, the fruit of the iconic Baobab tree, has received a Geographical Indication (GI) tag. This recognition is se...
- 16 fixed-dose combination drugs banned in India: Check full list hereFixed dose combination banned full list: India has banned 16 fixed-dose combination drugs, including certain antibiotics and antispasmodics...
- Indian pharma market's double-digit growth momentum is likely to continue further: EquirusThe Indian Pharmaceutical Market is set for continued double-digit growth. May's performance showed strong demand across all therapies. Chr...
- Kiran Mazumdar-Shaw eyes crown of world’s top insulin supplier for BioconIndian drugmaker Biocon aims to be the world's top insulin supplier within five years, capitalising on growing demand as major pharmaceutic...
- Indian pharma leaving generics era behind, but the Street hasn't caught up yet: Nandan KulkarniIndian pharma is shifting from generics to innovation. This transformation, extending to 2035, is creating significant new opportunities. C...
- India's weight-loss drug boom raises questions over healthcare prioritiesIndia's market for cheaper anti-obesity drugs has surged tenfold. While demand is high, especially among those with diabetes, concerns abou...
Load More
